文献速递妇科

尿石素A和B对子宫内膜异位细胞生长、黏附、迁移和侵袭的差异影响

The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro.
PubMed 文献 · Hum Reprod · 2021-01-01

本研究利用原代子宫内膜异位基质细胞、细胞系及3D模型,评估植物来源抗氧化剂尿石素A(UA)和B(UB)对子宫内膜异位细胞行为的影响。结果显示两者通过差异影响生长、黏附、迁移和侵袭,均表现出抑制子宫内膜异位发展相关细胞行为的效应。

要点

  • UA和UB抑制原代子宫内膜异位基质细胞及St-T1b细胞增殖。
  • UA和UB降低细胞迁移,且UA增加St-T1b细胞凋亡。
  • UA和UB下调MMP2、MMP3、MMP9及SDC1、ITGAV等基因表达。

核心结论

  • UA和UB通过差异影响生长、黏附、迁移和侵袭,在体外抑制子宫内膜异位细胞行为。

研究设计与样本

  • 研究使用6例子宫内膜异位患者的原代子宫内膜异位基质细胞、永生化子宫内膜基质细胞系St-T1b和子宫内膜异位上皮细胞系12Z进行体外实验。
  • 结果在12Z与1例患者原代子宫内膜异位基质细胞的三维共培养球体及3例独立供者的子宫内膜异位类器官中验证。

主要发现

  • 40 µM UA和20 µM UB显著降低原代子宫内膜异位细胞增殖(P < 0.001和P < 0.01)及St-T1b细胞增殖(P < 0.001和P < 0.05)。
  • 在St-T1b中,UA的平均半数抑制浓度(IC50)为39.88 µM,UB为79.92 µM;在12Z中,UA为40.46 µM,UB为54.79 µM。
  • 40 µM UA和20 µM UB均增加St-T1b细胞S期比例(P < 0.01和P < 0.05),且40 µM UA增加St-T1b细胞凋亡百分比(P < 0.05)。
  • 40 µM UA和20 µM UB处理24小时后均降低细胞迁移(P < 0.001);仅5 µM UB减少St-T1b黏附细胞数。
  • 在12Z中,40 µM UA和20 µM UB均显著降低细胞侵袭;UA下调MMP2(P < 0.001)、MMP3(P < 0.001)和MMP9(P < 0.05),UB下调MMP3(P < 0.05)、MMP9(P < 0.05)和RAC1(P < 0.05)。

关键数值与推荐

  • 40 µM UA和20 µM UB分别使原代子宫内膜异位细胞增殖显著下降(P < 0.001和P < 0.01)。
  • 80 µM UA和UB均显著降低子宫内膜异位球体活力(P < 0.05)。
  • 40和80 µM UA均显著抑制类器官发育/生长(P < 0.0001)。
  • 类器官中UA平均IC50为33.93 µM,UB为52.60 µM。

临床怎么用

  • 这些体外结果提示UA和UB可能作为子宫内膜异位症的潜在新治疗策略,但尚未在临床中验证。

局限性

  • 本研究仅基于体外子宫内膜异位模型,结果不能直接推广至临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the effects of plant-derived antioxidant compounds urolithin A (UA) and B (UB) on the growth and pathogenetic properties of an in vitro endometriosis model? SUMMARY ANSWER: Both urolithins showed inhibitory effects on cell behavior related to the development of endometriosis by differentially affecting growth, adhesion, motility, and invasion of endometriotic cells in vitro. WHAT IS KNOWN ALREADY: Endometriosis is one of the most common benign gynecological diseases in women of reproductive age and is defined by the presence of endometrial tissue outside the uterine cavity. As current pharmacological therapies are associated with side effects interfering with fertility, we aimed at finding alternative therapeutics using natural compounds that can be administered for prolonged periods with a favorable side effects profile. STUDY DESIGN, SIZE, DURATION: In vitro cultures of primary endometriotic stromal cells from 6 patients subjected to laparoscopy for benign pathologies with histologically confirmed endometriosis; and immortalized endometrial stromal (St-T1b) and endometriotic epithelial cells (12Z) were utilized to assess the effects of UA and UB on endometriotic cell properties. Results were validated in three-dimensional (3D) in vitro co-culture spheroids of 12Z and primary endometriotic stroma cells of one patient, and organoids from 3 independent donors with endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: The effects on cell growth were measured by non-radioactive colorimetric assay to measure cellular metabolic activity as an indicator of cell viability (MTT assay) and flow cytometric cell cycle assay on primary cultures, St-T1b, and 12Z. Apoptosis analyses, the impact on in vitro adhesion, migration, and invasion were evaluated in the cell lines. Moreover, Real-Time Quantitative Reverse Transcription polymerase chain reaction (RT-qPCR) assays were performed on primary cultures, St- T1b and 12Z to evaluate a plausible mechanistic contribution by factors related to proteolysis (matrix metalloproteinase 2, 3 and 9 -MMP2, MMP3, MMP9-, and tissue inhibitor of metalloproteinases -TIMP-1-), cytoskeletal regulators (Ras-related C3 botulinum toxin substrate 1 -RAC1-, Rho-associated coiled-coil containing protein kinase 2 -ROCK2-), and cell adhesion molecules (Syndecan 1 -SDC1-, Integrin alpha V-ITGAV-). Finally, the urolithins effects were evaluated on spheroids and organoids by formation, viability, and drug screen assays. MAIN RESULTS AND THE ROLE OF CHANCE: 40 µM UA and 20 µM UB produced a significant decrease in cell proliferation in the primary endometriotic cell cultures (P < 0.001 and P < 0.01, respectively) and in the St-T1b cell line (P < 0.001 and P < 0.05, respectively). In St-T1b, UA exhibited a mean half-maximum inhibitory concentration (IC50) of 39.88 µM, while UB exhibited a mean IC50 of 79.92 µM. Both 40 µM UA and 20 µM UB produced an increase in cells in the S phase of the cell cycle (P < 0.01 and P < 0.05, respectively). The same concentration of UA also increased the percentage of apoptotic ST-t1b cells (P < 0.05), while both urolithins decreased cell migration after 24 h (P < 0.001 both). Only the addition of 5 µM UB decreased the number of St-T1b adherent cells. TIMP-1 expression was upregulated in response to treating the cells with 40 µM UA (P < 0.05). Regarding the 12Z endometriotic cell line, only 40 µM UA decreased proliferation (P < 0.01); while both 40 µM UA and 20 µM UB produced an increase in cells in the G2/M phase (P < 0.05 and P < 0.01, respectively). In this cell line, UA exhibited a mean IC50 of 40.46 µM, while UB exhibited a mean IC50 of 54.79 µM. UB decreased cell migration (P < 0.05), and decreased the number of adherent cells (P < 0.05). Both 40 µM UA and 20 µM UB significantly decreased the cellular invasion of these cells; and several genes were altered when treating the cells with 40 µM UA and 10 µM UB. The expression of MMP2 was downregulated by UA (P < 0.001), and expression of MMP3 (UA P < 0.001 and UB P < 0.05) and MMP9 (P < 0.05, both) were downregulated by both urolithins. Moreover, UA significantly downregulated ROCK2 (P < 0.05), whereas UB treatment was associated with RAC1 downregulation (P < 0.05). Finally, the matrix adhesion receptors and signaling (co)receptors SDC1 and ITGAV were downregulated upon treatment with either UA or UB (P < 0.01 and P < 0.05, respectively in both cases). Regarding the effects of urolithins on 3D models, we have seen that they significantly decrease the viability of endometriosis spheroids (80 µM UA and UB: P < 0.05 both) as well as affecting their area (40 µM UA: P < 0.05, and 80 µM UA: P < 0.01) and integrity (40 µM UA and UB: P < 0.05, 80 µM UA and UB: P < 0.01). On the other hand, UA and UB significantly inhibited organoid development/outgrowth (40 and 80 µM UA: P < 0.0001 both; 40 µM UB: P < ns-0.05-0.001, and 80 µM UB: P < 0.01-0.001-0.001), and all organoid lines show urolithins sensitivity resulting in decreasing viability (UA exhibited a mean IC50 of 33.93 µM, while UB exhibited a mean IC50 of 52.60 µM). LARGE-SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: This study was performed on in vitro endometriosis models. WIDER IMPLICATIONS OF THE FINDINGS: These in vitro results provide new insights into the pathogenetic pathways affected by these compounds and mark their use as a potential new therapeutic strategy for the treatment of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded EU MSCA-RISE-2015 project MOMENDO (691058). The authors have no conflicts of interest to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Mc Cormack B, Maenhoudt N, Fincke V, et al. The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro. Hum Reprod. 2021. PMID: 33748857. doi:10.1093/humrep/deab053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。